Instrument Inactif

Communiqués ASLAN Pharmaceuticals Limited Taipei Exchange

Actions

6497

KYG054241099

Recherche biotechnologique et médicale

Communiqués

17/07/24	ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation	AQ
15/07/24	ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal	AQ
14/06/24	ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change	AQ
14/06/24	ASLAN PHARMACEUTICALS : ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE Form 6 K	PU
31/05/24	ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K	PU
21/05/24	ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference	AQ
09/05/24	ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	AQ
09/05/24	ASLAN Pharmaceuticals : 1Q2024 Financial Release	PU
07/05/24	ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event	AQ
02/05/24	ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics	AQ
30/04/24	ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab	AQ
24/04/24	ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference	AQ
22/04/24	ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024	AQ
22/04/24	ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients	AQ
22/04/24	ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K	PU
19/04/24	ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice	AQ
19/04/24	ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K	PU
15/04/24	ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update	AQ
12/04/24	ASLAN Pharmaceuticals : AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM - Form 6-K	PU
12/04/24	ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	AQ
12/04/24	ASLAN PHARMACEUTICALS : REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Form 6-K	PU
28/03/24	ASLAN Pharmaceuticals : H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	PU
27/03/24	Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders	AQ
12/03/24	ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering	AQ
11/03/24	ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients	AQ